UC3: VitaDX, Cerballiance Finistère and the COSS laboratory are collaborating within the framework of the "Collaborative innovation at the crossroads of different sectors" initiative.
Texte
UC3: VitaDX, Cerballiance Finistère and the COSS laboratory are collaborating within the framework of the "Collaborative innovation at the crossroads of different sectors" initiative.
The Characterisation of Urothelial Cancer Cells "UC3" project funded by the Brittany region, Rennes Métropole and the ERDF aims to deepen our understanding of the fluorescence phenomenon exploited as part of the development of a solution for the early diagnosis of bladder cancer, combining white light and fluorescence imaging with artificial intelligence.
The UC3 project has been approved by Atlanpole Biotherapies and Images & Réseaux competitiveness clusters and is also supported by ID2Santé.